Complement C5 from Human Serum, CAS No.80295-53-0
Disponible
SKU
np001101
Complement C5 is part of the terminal sequence in the complement pathway. In particular, it is cleaved into C5a and C5b which are responsible for chemotaxis, inflammation, and initiating the formation of the membrane attack complex (MAC). Drugs that inhibit complement C5 have been used in Paroxysmal nocturnal hemoglobinuria (PNH) patients to lessen thrombotic complications by lessening intravascular hemolysis.
Complement component C5 is processed by convertase enzymes in a cascade modulated in a unique way. The multi-subunit catalytic complex initially shows little activity against C5, but instead cleaves C3. A C3 cleavage product C3b covalently attaches to the complex and shifts its specificity to C5 by a factor of 1000.
Purity: >=95% by SDS-PAGE.
Reacts to C5 antisera on Western Blot
Not tested for biological activity.
Prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests.
Más Información
| Sinónimos | Complement component C5 | C5D | C5a | C5b | ECLZB | CPAMD4 |
|---|---|
| Product Description | Complement C5 is part of the terminal sequence in the complement pathway. In particular, it is cleaved into C5a and C5b which are responsible for chemotaxis, inflammation, and initiating the formation of the membrane attack complex (MAC). Drugs that inhibit complement C5 have been used in Paroxysmal nocturnal hemoglobinuria (PNH) patients to lessen thrombotic complications by lessening intravascular hemolysis. Complement component C5 is processed by convertase enzymes in a cascade modulated in a unique way. The multi-subunit catalytic complex initially shows little activity against C5, but instead cleaves C3. A C3 cleavage product C3b covalently attaches to the complex and shifts its specificity to C5 by a factor of 1000. Purity: >=95% by SDS-PAGE. Reacts to C5 antisera on Western Blot Not tested for biological activity. Prepared from plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests. |
| Especificaciones y pureza | Bioactive, BioReagent, Native, ≥90%(SDS-PAGE), Protein concentration: 0.95-1.2 mg/ml |
| Bioactividad | Titer >100,000 C5H50 U/mg; >60% of C5 activity in NHS on a mg/mg basis. |
| Número de adhesión | P01031 |
| CAS | 80295-53-0 |
| Forma | Frozen liquid in PBS, pH 7.4 |
| Concentración | Protein concentration: 0.95-1.2 mg/ml |
| Condiciones de almacenamiento de almacenamiento | Store at -80°C,Avoid repeated freezing and thawing |
| Enviado en | Dry ice packs + Cold packs |
| Estabilidad y almacenamiento | Store at -80℃ long term (3 years). Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| Definición de unidad | One C5H50 unit measured by classical pathway activation is defined as the amount of C5 required to yield 50% lysis of 3 x 10⁷ EA when incubated in the presence of the recommended volume of C5-Dpl serum for 30 minutes at 37°C in a total reaction volume of |
Reseñas
Reseñas de cliente
Remind me later